Clinical Trial Update: PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM) [Phase 1]

View source ↗

Summary

Phase 1 study assessing pharmacokinetics, pharmacodynamics, and within-subject variability after a single inhaled dose of Afrezza (Technosphere insulin) in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 1 Diabetes Mellitus

Drugs mentioned

• Afrezza (Technosphere insulin)

Snippet

Sponsor: Mannkind Corporation | Conditions: Type 1 Diabetes Mellitus | Phase 1 | Status: COMPLETED